Cargando…

Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan

OBJECTIVES: We conducted an analysis of first-time tolvaptan users (≥80 years old) to determine the factors associated with the prognosis of elderly patients with heart failure. METHODS: We retrospectively analyzed 66 consecutive patients with worsening heart failure (aged ≥80 years) who were admitt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Masakazu, Hayashi, Mutsuharu, Yamada, Ryo, Ishiguro, Tomoya, Fujiwara, Wakaya, Ishii, Hideki, Naruse, Hiroyuki, Watanabe, Eiichi, Ozaki, Yukio, Izawa, Hideo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fujita Medical Society 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206904/ https://www.ncbi.nlm.nih.gov/pubmed/37234387 http://dx.doi.org/10.20407/fmj.2021-027

Ejemplares similares

Circulating miR-489 as a potential new biomarker for idiopathic dilated cardiomyopathy
por: Ishiguro, Tomoya, et al.
Publicado: (2021)

Predictive impact of early mobilization on rehospitalization for elderly Japanese heart failure patients
por: Kono, Yuji, et al.
Publicado: (2019)

Urinary Liver-Type Fatty-Acid-Binding Protein Predicts Long-Term Adverse Outcomes in Medical Cardiac Intensive Care Units
por: Naruse, Hiroyuki, et al.
Publicado: (2020)

Effect of cardiac rehabilitation on circulating microRNA expression in heart failure: a preliminary study
por: Yamada, Ryo, et al.
Publicado: (2021)

Impact of physical function on indeterminable anaerobic threshold in patients with heart failure
por: Ueda, Sayano, et al.
Publicado: (2021)

Combined Assessment of D-Dimer with the Get with the Guidelines—Heart Failure Risk Score and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Acute Decompensated Heart Failure with Preserved and Reduced Ejection Fraction
por: Naruse, Hiroyuki, et al.
Publicado: (2021)

A simple proteinuria-based risk score predicts contrast-associated acute kidney injury after percutaneous coronary intervention
por: Fujiwara, Wakaya, et al.
Publicado: (2022)

Predicting acute kidney injury using urinary liver-type fatty-acid binding protein and serum N-terminal pro-B-type natriuretic peptide levels in patients treated at medical cardiac intensive care units
por: Naruse, Hiroyuki, et al.
Publicado: (2018)

Association between inflammation and skeletal muscle proteolysis, skeletal mass and strength in elderly heart failure patients and their prognostic implications
por: Koshikawa, Masayuki, et al.
Publicado: (2020)

Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure
por: Niikura, Hiroki, et al.
Publicado: (2017)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure
por: Ogawa, Hayato, et al.
Publicado: (2015)

Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure
por: Okada, Tomoaki, et al.
Publicado: (2023)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Tolvaptan should be used very carefully in very elderly patients
por: Kahraman, Fatih, et al.
Publicado: (2018)

Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation
por: Harada, Masahide, et al.
Publicado: (2020)

Effect of pulmonary vein isolation on rotor/multiple wavelet dynamics in persistent atrial fibrillation, association with vagal response and implications for adjunctive ablation
por: Nishimura, Asuka, et al.
Publicado: (2022)

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016)

Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure
por: Katsumata, Mari, et al.
Publicado: (2017)

Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS)
por: Ozaki, Yukio, et al.
Publicado: (2022)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan
por: Fujioka, Kensuke, et al.
Publicado: (2019)

Serum angiotensin‐converting enzyme levels indicating early sarcoidosis diagnosis and immunosuppressive therapy efficacy
por: Kawai, Hideki, et al.
Publicado: (2023)

Early Initiation of Tolvaptan is Associated with Early Discharge in Elderly Heart Failure Patients
por: Kiuchi, Shunsuke, et al.
Publicado: (2021)

A Resuscitated Adult With Left Main Coronary Artery Ostial Atresia and Graves’ Disease: 10-Year Follow-up
por: Kobayashi, Masakazu, et al.
Publicado: (2021)

Frequency analysis of ultrasonic echo intensities of the skeletal muscle in elderly and young individuals
por: Nishihara, Ken, et al.
Publicado: (2014)

Diagnosis of isolated cardiac sarcoidosis based on new guidelines
por: Kawai, Hideki, et al.
Publicado: (2020)

Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease
por: Ishii, Junnichi, et al.
Publicado: (2022)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

A case report with shock induced by tolvaptan in an elderly patient with congestive heart failure
por: Zhang, Zhi-gang, et al.
Publicado: (2018)

MORPHOLOGIC CHARACTERIZATION AND QUANTIFICATION OF SUPERFICIAL CALCIFICATIONS OF THE CORONARY ARTERY―IN VIVO ASSESSMENT USING OPTICAL COHERENCE TOMOGRAPHY―
por: MATSUMOTO, MASAYA, et al.
Publicado: (2012)

LEFT VENTRICULAR DYSSYNCHRONY IN PATIENTS WITH MODERATE CORONARY STENOSIS AND BORDER LINE FRACTIONAL FLOW RESERVE
por: SHIBATA, YOHEI, et al.
Publicado: (2015)

Long-Term Tolvaptan Treatment in Refractory Heart Failure
por: Imamura, Teruhiko, et al.
Publicado: (2019)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Circadian expressions of cardiac ion channel genes in mouse might be associated with the central clock in the SCN but not the peripheral clock in the heart
por: Tong, Maoqing, et al.
Publicado: (2012)

Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
por: Komiya, Shiro, et al.
Publicado: (2022)

Echocardiographic characteristics of patients with acute heart failure requiring tolvaptan: a retrospective study
por: Nakada, Yasuki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l4h9dq1bjevjkhhuh38ldvnenp